-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Recently (November 13, 2021), CG Oncology disclosed the very eye-catching Phase II clinical trial data of its oncolytic virus drug CG0070 combined with K drug
NMIBC urgently needs new treatments
NMIBC urgently needs new treatmentsBladder cancer is one of the common malignant tumors of the urinary system (NMIBC accounts for 70% to 80% of bladder cancers), and has the characteristics of easy invasion, recurrence, drug resistance, and multicenter
At present, the treatment methods for NMIBC are very limited.
Single-agent CR was significantly better than K-drug
Single-agent CR was significantly better than K-drugCG0070 is an engineered adenovirus type 5 (Ad5) oncolytic virus drug developed by CG Oncology
Previously, CG Oncology has disclosed the dazzling data of the Phase II clinical trial (BOND II) of the single drug of CG0070
The CR rate of combined K drug is as high as 100%
The CR rate of combined K drug is as high as 100%In addition to single drugs, CG0070 is also trying to use the combined effect of immune checkpoint inhibitors
The clinical data of CG0070 combined with K drug released this time are also amazing
CG-007 has demonstrated extraordinary efficacy in high-risk NMIBC patients who do not respond to BCG, whether it is a single drug or a combination drug.
Domestic Lepu Bio has the authorization to develop, manufacture and commercialize this product in China
Lepu Bio is also currently planning to initiate a clinical trial of CG0070 in combination with its core product HX008 for patients with advanced NMIBC (Putlimumab (HX008) is an anti-PD-1 monoclonal antibody product of Lepu Bio.
Summarize
SummarizeAs an important means in the current field of tumor immunotherapy, the therapeutic potential of oncolytic virus drugs in various diseases such as malignant tumors has attracted more and more attention from scientific research and industrial circles
Thanks to the advancement of genetic engineering technology, the development of oncolytic viruses in China has become increasingly active.
(Source: Biopharmaceutical Editor)
References:
1.
2.
3.
